Jamie Pearson has been a highly respected leader in the cannabis industry for over a decade. Her “in the trenches” operational success and deep, global relationships led her to be coined “Wonder Woman” in the 2023 Women of Influence issue of Cannabis Now Magazine. Fluent in German, Jamie spent decades in the global real estate investment and finance world on three continents. She currently sits on the advisory boards of Dope Drinks, Marley One, Cellotex Dev Ltd, Global Cannabis Network Collective (GCNC), Lift & Co, and Alpen Group AG.
Jamie founded and leads The New Holland Group, a global consulting firm serving clients with international business development & strategy, seed to sale operations, branding & marketing, effective capital raising, executive coaching, cross border IP licensing, celebrity partnerships, buy & sell side M&A, and financial turnarounds. Client referrals have been New Holland Group’s only source of business and business is booming!
Before New Holland Group, Jamie spent seven years, including three as the President & CEO, of Bhang Inc. [CSE:BHNG] one of the world’s most-awarded and recognized cannabis edible brands, famous for its infused chocolate bars. She led the company’s diverse executive team, managed the “expansion through licensing” plan, ran the capital markets division, and was the face of the brand – catapulting Bhang from a California favorite to a multi-state and multi-national phenomenon. When Jamie exited Bhang the brand had been distributed in 7 US states and 10 countries through licensing deals with the likes of Trulieve, [CSE:TRUL], Indiva [TSX:NDVA] and Origin House [CSE:OH] (now Cresco). Jamie served four years as the Vice Chairman of Bhang’s Board and served on the Board’s audit committee.
Jamie is a popular speaker with competence in the areas of global expansion, ESG, IP & brand licensing, real estate acquisition, creative deal structuring, celebrity partnerships, business development, and leadership. Jamie can be reached at jamie@new-holland.group.

Lisa Haag is an entrepreneur in the German cannabis industry. She holds a degree in business administration (IUBH, Bad Honnef) and a Bachelor of Business (Victoria University, Melbourne) in hospitality management. Lisa worked many years for companies in strategic and regional sales for FM-services (IFM, TFM, etc.).

Lisa has been active in the cannabis industry since 2017. In July 2018, she founded MJ_UNIVERSE GmbH, a publisher of digital products (e.g. Krautinvest.de) and a collaborative network to connect companies along the value chain of cannabis. She works with a network of specialised experts to consult companies looking to navigate the European cannabis ecosystem. As an entrepreneur, she is committed to projects dedicated to accelerate cannabis as a medicine, to advocacy for a more progressive and realistic cannabis regulatory framework and to activities to mainstream cannabis. With MJ_UNIVERSE, Lisa’s mission is to unlock the full potential of cannabis.

Lisa is part of the board of the BvCW e.V. and an active member of the Cannafem Network – a network for women, hemp and cannabis.

Peter Homberg specialises in life sciences, IP and corporate law, and M&A transactions.
He particularly advises companies in the pharmaceutical, diagnostics, medical device and biotechnology sectors on research and development contracts, collaboration agreements, cross-border IP licensing and IP strategies. He also has extensive experience in advising on compliance issues and advises companies extensively in the field of medical cannabis.
Peter is a frequent speaker at seminars and conferences and is the author of numerous articles and other publications on corporate or IP law in the areas of life sciences and medical cannabis. In addition, he has extensive transaction experience in Southeast Asia.
His clients include:
Start-ups
Medium-sized companies
Listed companies
Nationally and internationally operating corporate groups
Financial investors
Strategic investors

Experience Highlights
DEMECAN GmbH: Preparation of a legal opinion on the compatibility of the legalization of cannabis for recreational purposes in Germany with international and European law. Identification of possible solutions to overcome obstacles under international and European law.
Canopy Growth Corp.: Advising the subsidiary of one of Canada’s leading medical cannabis providers in connection with the acquisition of the Storz & Bickel GmbH & Co. KG group of companies for a total of €135 million.
DEMECAN GmbH: Preparation of a comprehensive legal opinion on the legal hurdles to the legalization of cannabis for recreational purposes and analysis of possible legal solutions.
Proteona Pte. Ltd.: Advising the biotechnology company on the conclusion of an exclusive worldwide license agreement with the National University of Singapore (NUS).
Canadian supplier of medical cannabis: Advising in connection with the conclusion of a joint venture agreement with a German wholesaler of pharmaceuticals.
Scil Technology GmbH: Advising on the out-licensing of a program for the regenerative treatment of osteoarthritis and cartilage defects to Sanofi.
Scil Technology GmbH: Advising on the sale of its service and production division to Nanohale AG.
German biotechnology company: Advising on the sale of a technology for the treatment of certain forms of heart failure.
German mid-sized pharmaceutical company: Advising on the out-licensing and distribution of an API for the treatment of interstitial cystitis to a US-based multinational pharmaceutical company.
Large US-based pharmaceutical company: Advising on the due diligence of a technology portfolio in advance of the in-licensing of a technology for the production of vaccines.
Swiss biotech company: Advising on a planned collaboration with a French multinational pharmaceutical company.
German-Singaporean biotech company: Advising on the in-licensing of a key diagnostic technology from the National University of Singapore.
French venture capital fund: Advising on the acquisition of a block of shares in a German biotech company.
Medium-sized pharmaceutical company: Advising on the restructuring of sales in Portugal and various other European countries.
Various clients: Advising in connection with transactions in the life sciences sector, including technology transfer agreements, research and development agreements, corporate transactions (mergers & acquisitions), private equity transactions, arbitration proceedings and litigation.

Kai has been a business and corporate lawyer in Germany since 2003, gaining wide range of experiences in the process. He is very familiar with the interconnectivity between national and European regulations, especially in regard to consumer protection, product safety and emerging new cannabis products. He has engaged in advocacy relating to cannabis beginning in early stages of his studies at Philipps University Marburg when the German Supreme Court ruled that small amounts of cannabis should not be criminalized. After medical cannabis was legalized, Kai started a legal blog (canna-biz.legal) on all the relevant new developments in the emerging cannabis market and became a legal expert especially for CBD products. He regularly speaks at international cannabis conferences on topics of the German and European legal framework. Lastly he spoke at the ICBC 2021 in Berlin and Zurich, at the CB Expo 2021 in Zurich, at Re:publica in Berlin and EuroAMCBC in Prague on the legal framework for a future recreational cannabis market in Germany, at the First Asian Hemp Summit in Hong Kong and at the Cannabis Law Institute in New York. He has published articles at Prohibition Partners and in German law journals. Kai and his Law firm KFN+ consult major CBD and medical cannabis companies. Kai is also legal advisor to the European Industrial Hemp Association (EIHA), which is working on a Novel Food joint application for different CBD products.

Memberships: German Bar Association (DAV), International Cannabis Bar Association (INCBA, Member of Advisory Board), European Industrial Hemp Association (EIHA), German Hemp Association (DHV), Law Enforcement Against Prohibition (LEAP Germany), Branchenverband Cannabiswirtschaft (BvCW).

Born in Löhne/Westf. in 1972, studied law at the Universities of Marburg, Adelaide (Australia), Cologne, legal expert at the press center of the German Federal Diet, worked for the Berlin District Court, for the Director of Public Prosecution in Berlin, for the Office for the Protection of the Constitution and the Hong Kong Consulate General.

Gašper Friškovec is a licensed attorney in Slovenia, and has over a decade of practice in advising clients and their legal representation on economic, regulatory, and political matters before the highest Slovenian and international courts. He is a graduate of the Faculty of Law at the University of Ljubljana, where he is also earning his doctorate while specializing in administrative law. His experience has given him a unique perspective on public policy and law within both Slovenia and the EU. Gasper is able to work adeptly within a variety of regulatory frameworks. He brings a pragmatic and disruptive approach to crafting innovative solutions for the complex challenges facing businesses in this emerging industry.

Daniel Haymann specializes in corporate and commercial law. Thanks to his extensive business experience, he has a good sense for new markets and understands the requirements for market launch and scale-up strategies. As an interdisciplinary and hands-on advisor, his focus is on investments, venture capital and financing transactions as well as regulatory issues in the healthcare and consumer goods sectors.
He has been advising investors, start-ups, and vertically integrated companies along the value chain, including on regulatory matters relating to THC, CBD and other cannabinoids and psychedelic compounds, on GMP and GDP standards, foodstuff and cosmetics regulations as well as authorization procedures before Swissmedic, the Swiss Agency for Therapeutic Products.
Daniel is the co-founder and co-chair of the European offshoot of the International Cannabis Bar Association (INCBA Europe). In addition, as a dual Swiss-Israeli citizen, he focuses on supporting clients with ties to Israel and strengthening the corresponding business relationships.
Prior to his career as a lawyer, Daniel spent over 10 years as a commodities trader for multinational corporations in senior management positions.

Will Muecke is a co-founding managing member of Artemis Growth Partners, an ESG and impact-oriented private equity platform dedicated to investing 100% in the cannabis industry on a worldwide basis.

Artemis Growth Partners oversees US $400 million in mission-driven discretionary assets under management (AUM) invested in the global cannabis value chain, including branded products, distributors, value-added service providers, ancillary operators, and science-driven research and development platforms.

Will was co-founding managing partner of CoreCo Private Equity, a 2017 GIIRS-rated “Best for the World” ESG-focused impact fund backed by investors including the IFC/World Bank, and the multilateral/development banks of Germany, Norway, Switzerland, Belgium, the IADB, and UHNW individuals and European family offices (CoreCo was fully deployed as of July 2017).

Will was formerly the global co-head of the healthcare services sector in the healthcare investment banking group at Goldman, Sachs & Co. (New York).

Will maintains extensive personal and professional networks in Europe, US, and Latin America.

Will resides in London and is the Chief Investment Officer for Artemis Growth Partners.

Artemis Growth Partners website: www.artemisgrowth.com

Linkedin profile: www.linkedin.com/in/wmuecke/

George Bellow is a visionary entrepreneur and strategic leader with over 16 years of experience in sales, business development, and startup growth across industries like pharmaceuticals, virtual reality, and fintech. As Co-Founder of SOMAÍ Pharmaceuticals, George successfully raised €30 million, playing a pivotal role in establishing the company’s sales and distribution networks across Europe. His work secured partnerships in key markets such as Germany, the UK, Switzerland, and Poland, positioning SOMAÍ as a leading name in the European medical cannabis sector.
Before SOMAÍ, George founded Belka VR, a trailblazing virtual reality company that gained global recognition. He also spearheaded international sales growth for UNICUM, expanding its reach to over 24 countries. In Russia, George co-founded Mili, a fintech pioneer in microloans, scaling it to become the largest provider in the country with over $13 million in revenue before a successful exit. His strategic foresight helped raise €5 million for Mili, fueling its rapid growth and market leadership.
With executive education from MIT Sloan and an MBA from Moscow School of Management Skolkovo, George brings unmatched expertise in strategic planning, capital raising, and business scaling, driving impactful results and innovation in every venture he leads.

Will Muecke is a co-founding managing member of Artemis Growth Partners, an ESG and impact-oriented private equity platform dedicated to investing 100% in the cannabis industry on a worldwide basis.

Artemis Growth Partners oversees US $400 million in mission-driven discretionary assets under management (AUM) invested in the global cannabis value chain, including branded products, distributors, value-added service providers, ancillary operators, and science-driven research and development platforms.

Will was co-founding managing partner of CoreCo Private Equity, a 2017 GIIRS-rated “Best for the World” ESG-focused impact fund backed by investors including the IFC/World Bank, and the multilateral/development banks of Germany, Norway, Switzerland, Belgium, the IADB, and UHNW individuals and European family offices (CoreCo was fully deployed as of July 2017).

Will was formerly the global co-head of the healthcare services sector in the healthcare investment banking group at Goldman, Sachs & Co. (New York).

Will maintains extensive personal and professional networks in Europe, US, and Latin America.

Will resides in London and is the Chief Investment Officer for Artemis Growth Partners.

Artemis Growth Partners website: www.artemisgrowth.com

Linkedin profile: www.linkedin.com/in/wmuecke/

Chris Day is a highly sought-after consultant and strategic advisor to investors seeking to identify and capitalize on emerging global opportunities in the cannabis industry. As the co-founder of Project Evolve and the Global Cannabis Network Collective (GCNC), an exclusive network for C-suite executives, Chris is a recognized authority on global market trends, partnership-driven growth, and international business development in the cannabis sector.
With over two decades of experience in business management, marketing, and communications, Chris has a proven track record of building profitable ventures and guiding investors toward high-performing opportunities. His career includes leading the marketing and international relations efforts for MJBizCon, the world’s largest B2B cannabis conference, where he helped achieve record-breaking growth. He also served as CEO of Gateway Proven Strategies, a multinational consulting firm dedicated to fostering sustainable, responsible, and lucrative cannabis markets worldwide.
Under Chris’s leadership, GCNC has become a hub for deal flow, knowledge-sharing, and high-value business connectivity across the globe. His ability to identify untapped markets, mitigate risks, and align stakeholders for strategic success makes him an invaluable partner for investors aiming to maximize returns in the cannabis industry.
A graduate of Colorado State University, Chris is a dual resident of Colorado and Quintana Roo, Mexico. While his roots are in the United States, his global perspective stems from years of international travel and market exploration. Whether connecting investors to emerging opportunities or advising on high-impact ventures, Chris’s unique combination of expertise, vision, and passion for the cannabis ecosystem ensures measurable results for his clients.